Search results for: 'pfa0 testing in soil'

This research service analyzes the U.S. cancer biomarker testing market from 2009 to 2017. Topics include an overview of the market, along with definitions, metrics, drivers, and restraints. Also offered is an evaluation of ongoing technology trends and major market competitors and their corresponding market shares and product offerings. Based on t...

Major automotive OEMs globally are now incorporating active safety and automated vehicle technologies in their future vehicle line-ups to enhance safety and driver comfort. To gauge the suitability of each technology, continuous testing and validation is a must. Based on supportive legislation, several regions across the globe have been identified ...

23 Jun 2016  |  North America  |  Market Research

Growth Opportunities in the US Point-of-care Testing Market

Digital Health Meets Point of Care—Emergence of Mobile Molecular Diagnostics

Infographics

×

The US point-of-care testing (POCT) study provides an extensive analysis for 13 segments: hematology, urinalysis, infectious disease, cardiac, HbA1c, glucose, fecal occult blood test/fecal immunochemical test (FOBT/FIT), coagulation PT/INR, coagulation APTT/ACT, cholesterol, pregnancy, drugs of abuse, and blood gas and electrolytes. Key trends and ...

Management of infectious diseases remains a critical challenge for public health professionals who face increasing demand to control the spread of existing and novel diseases. To provide appropriate healthcare assistance, it is imperative to diagnose the exact form of infection from an array of complicated symptoms expressed by the host. As the out...

In 2003, the first human genome sequence was produced, with a production cost between $500 million and $1 billion. However, since 2008, when next-generation sequencing (NGS) approaches entered the research setting, there has been a significant decline in sequencing costs. These approaches allow either the whole genome (via whole-genome sequencing [...

The main objective of this research is to estimate test volumes and unit prices for a wide variety of LDTs (genetic) and a few high volume FDA tests for selective therapeutic areas. The tests are categorized by their intended uses across the diagnostic spectrum (risk assessment, screening, diagnosis, staging and prognosis, therapy selection, therap...

This research service on the global pharma extractables and leachables (E&L) testing market addresses the market sizing, emerging trends, and technologies, and provides a snapshot of the key participants in the market. The base year for the deliverable is 2015 while forecasts have been provided from 2016 to 2020. The pharma E&L testing market is ...

Accelerated reforms due to COVID-19 and technologically advanced sample-in-answer-out portable, web-connected, encrypted devices that provide results in a few minutes changed the diagnostic healthcare industry. Decentralized testing empowers clinicians to make lifesaving decisions for the patient. It shortens supply chain lag time, saves costs of i...

Cardiac troponin (cTn) biomarkers are the gold standard in myocardial infarction (MI) diagnosis, leading healthcare professionals to use cTn diagnostics. In addition, a rising number of patients visit emergency departments (EDs) with cardiac complaints, increasing ED demand for kits that can rapidly rule MI in or out. Both factors serve as signif...